Abstract
Overview
Introduction
The osteoporosis market is due a major upheaval when market leader Fosamax
(alendronate) loses its US patent. The resultant heightened competition will
force market players to implement radical lifecycle management strategies to
safeguard their franchise revenue. New market entrants provide further
complexity to the competitive landscape but will also drive market growth over
the next ten years.
Scope
- This report focuses on the leading therapies used in osteoporosis, with
sales and volume country- and indication-specific forecasts to 2016
- Assessment of current and future opportunities and threats in the
osteoporosis market across the seven major pharmaceutical markets
- Future market events that are expected to affect drug revenues are
discussed and quantified for each of the seven major markets
- Lifecycle management case studies show how previously successful
strategies should be applied in today' s market
Highlights
Reformulations of marketed products have helped rejuvenate the calcitonin and
bisphosphonate markets amid genericization. Arguably the most exciting is the
Roche' s Boniva (ibandronate) reformulation which will generate substantial
revenue as both an oral monthly and injectable quarterly product.
Following a number of recent reports that have concluded that vitamin D and
calcium supplementation decreases the risk of cancer there is further support
for the strategy to include a popular supplementary medication as either a
combination pill or separately within the prescription brand packaging.
Eli Lilly has successfully launched two very different therapies to treat
osteoporosis. Evista (raloxifene) and Forteo (teriparatide) The two products
have been successful, being the third and fourth highest selling products on
the osteoporosis market. In 2006, Evista generated sales of $739m and Forteo
returned revenue of $574m.
Reasons to Purchase
- Assess the impact of events such as patent expiries and new product
launches on the osteoporosis sales of key marketed products
- Quantify the future size of the osteoporosis market, in terms of volume
and value, in each of the seven major markets
- Identify key lifecycle management strategies that can ensure long term
growth in the competitive osteoporosis market
| 
View Cart
